These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28257086)

  • 1. High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors.
    Pujols J; Peña-Díaz S; Conde-Giménez M; Pinheiro F; Navarro S; Sancho J; Ventura S
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
    Vittorio S; Adornato I; Gitto R; Peña-Díaz S; Ventura S; De Luca L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1727-1735. PubMed ID: 32924648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical Chaperones as Novel Drugs for Parkinson's Disease.
    Pujols J; Peña-Díaz S; Pallarès I; Ventura S
    Trends Mol Med; 2020 Apr; 26(4):408-421. PubMed ID: 32277934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
    Singh SK; Dutta A; Modi G
    Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson's disease.
    Hideshima M; Kimura Y; Aguirre C; Kakuda K; Takeuchi T; Choong CJ; Doi J; Nabekura K; Yamaguchi K; Nakajima K; Baba K; Nagano S; Goto Y; Nagai Y; Mochizuki H; Ikenaka K
    Sci Rep; 2022 Jan; 12(1):351. PubMed ID: 35013421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors.
    Jha NN; Kumar R; Panigrahi R; Navalkar A; Ghosh D; Sahay S; Mondal M; Kumar A; Maji SK
    ACS Chem Neurosci; 2017 Dec; 8(12):2722-2733. PubMed ID: 28872299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease.
    Macchi F; Deleersnijder A; Van den Haute C; Munck S; Pottel H; Michiels A; Debyser Z; Gerard M; Baekelandt V
    J Neurosci Methods; 2016 Mar; 261():117-27. PubMed ID: 26620202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA).
    Herva ME; Zibaee S; Fraser G; Barker RA; Goedert M; Spillantini MG
    J Biol Chem; 2014 Apr; 289(17):11897-11905. PubMed ID: 24584936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State.
    Kurnik M; Sahin C; Andersen CB; Lorenzen N; Giehm L; Mohammad-Beigi H; Jessen CM; Pedersen JS; Christiansen G; Petersen SV; Staal R; Krishnamurthy G; Pitts K; Reinhart PH; Mulder FAA; Mente S; Hirst WD; Otzen DE
    Cell Chem Biol; 2018 Nov; 25(11):1389-1402.e9. PubMed ID: 30197194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexation of NAC-Derived Peptide Ligands with the C-Terminus of α-Synuclein Accelerates Its Aggregation.
    Jha NN; Ranganathan S; Kumar R; Mehra S; Panigrahi R; Navalkar A; Ghosh D; Kumar A; Padinhateeri R; Maji SK
    Biochemistry; 2018 Feb; 57(5):791-804. PubMed ID: 29286644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
    Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
    ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins.
    Casalino E; Stine LB; Corin AJ; Thai CT; Quiroz J; Wilson SC; Labow M; Mittal S
    SLAS Discov; 2022 Sep; 27(6):349-357. PubMed ID: 35580766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZPD-2, a Small Compound That Inhibits α-Synuclein Amyloid Aggregation and Its Seeded Polymerization.
    Peña-Díaz S; Pujols J; Conde-Giménez M; Čarija A; Dalfo E; García J; Navarro S; Pinheiro F; Santos J; Salvatella X; Sancho J; Ventura S
    Front Mol Neurosci; 2019; 12():306. PubMed ID: 31920537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of formation of α-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease.
    Faria C; Jorge CD; Borges N; Tenreiro S; Outeiro TF; Santos H
    Biochim Biophys Acta; 2013 Aug; 1830(8):4065-72. PubMed ID: 23608058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning.
    Horne RI; Andrzejewska EA; Alam P; Brotzakis ZF; Srivastava A; Aubert A; Nowinska M; Gregory RC; Staats R; Possenti A; Chia S; Sormanni P; Ghetti B; Caughey B; Knowles TPJ; Vendruscolo M
    Nat Chem Biol; 2024 May; 20(5):634-645. PubMed ID: 38632492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.